Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 5.5% – Should You Buy?

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) traded up 5.5% on Monday . The stock traded as high as $6.50 and last traded at $6.36. 5,209,043 shares were traded during trading, a decline of 23% from the average session volume of 6,721,588 shares. The stock had previously closed at $6.03.

Wall Street Analysts Forecast Growth

RXRX has been the topic of several recent research reports. Jefferies Financial Group lowered their price objective on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a research report on Tuesday, September 3rd. Needham & Company LLC reissued a “buy” rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a report on Wednesday, December 11th. Finally, Leerink Partners cut their price objective on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a report on Tuesday, September 3rd. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $9.25.

Recursion Pharmaceuticals Trading Up 3.6 %

The firm has a market capitalization of $2.08 billion, a price-to-earnings ratio of -4.73 and a beta of 0.85. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. The company has a 50 day moving average price of $6.77 and a two-hundred day moving average price of $7.16.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The company had revenue of $26.08 million for the quarter, compared to analyst estimates of $12.62 million. During the same quarter in the prior year, the company posted ($0.43) earnings per share. The business’s revenue was up 147.6% on a year-over-year basis. On average, research analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Insider Activity at Recursion Pharmaceuticals

In other news, Director Blake Borgeson sold 11,447 shares of the stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $6.22, for a total value of $71,200.34. Following the completion of the sale, the director now directly owns 7,098,428 shares in the company, valued at $44,152,222.16. This represents a 0.16 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, COO Tina Marriott sold 6,000 shares of the firm’s stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $7.00, for a total transaction of $42,000.00. Following the completion of the transaction, the chief operating officer now directly owns 521,138 shares in the company, valued at approximately $3,647,966. This represents a 1.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 107,788 shares of company stock valued at $724,691. 15.75% of the stock is owned by corporate insiders.

Institutional Trading of Recursion Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the business. ARK Investment Management LLC boosted its holdings in shares of Recursion Pharmaceuticals by 16.4% during the 3rd quarter. ARK Investment Management LLC now owns 32,769,186 shares of the company’s stock worth $215,949,000 after purchasing an additional 4,626,268 shares during the last quarter. State Street Corp boosted its stake in Recursion Pharmaceuticals by 47.1% during the third quarter. State Street Corp now owns 12,870,272 shares of the company’s stock worth $84,815,000 after buying an additional 4,120,685 shares during the last quarter. Lingotto Investment Management LLP grew its holdings in Recursion Pharmaceuticals by 69.0% in the 2nd quarter. Lingotto Investment Management LLP now owns 3,675,077 shares of the company’s stock valued at $27,563,000 after buying an additional 1,500,000 shares in the last quarter. Ghisallo Capital Management LLC acquired a new stake in shares of Recursion Pharmaceuticals in the 2nd quarter worth $8,250,000. Finally, Perceptive Advisors LLC purchased a new position in shares of Recursion Pharmaceuticals during the 2nd quarter worth $5,769,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.